

PACE/PAP/CRDP/SPBP Provider Bulletin

April 30, 2025

Commonwealth of Pennsylvania Drug Manufacturers' Rebate Program Non-Participating Manufacturers

REVISED

The Department of Aging has resolved the outstanding rebate issues with 1 of the manufacturers contained on the list distributed on March 13, 2025.

73625	Bristol Myers Squibb	Camzyos®
-------	----------------------	----------

The manufacturer labelers identified below will continue to no longer have their products reimbursed by PACE, PAP, CRDP, and SPBP effective April 14, 2025.

Providers using products from these manufacturers may wish to explore alternative sources.

Labeler Number	Drug Manufacturer Name	Medication(s) Affected
68001	Bluepoint	carvedilol, lisinopril
60687	American Health Packaging	ipratropium albuterol
64679	Wockhardt	bupropion XL
60432	Morton Grove	amantadine
42806	EPIC	icosapent ethyl, methylprednisone
65219	Fresenius Kabi	ampicillin sodium, bumetanide
70842	Melinta Therapeutics	Baxdela®, Toprol XL®, Vabomere®, Kimyrsa®
80610	Arcutis Biotherapeutics	Zoryve®
81672	Dermavant Sciences	Vtama®
82036	Zambon USA, LTD	fosfomycin tromethamine
82154	Pharma & GMBH	Pegasys®, Rubraca®
82576	Madrigal Pharmaceuticals	Rezdiffra®
72482	Sobi	Vonjo®
73289	Aucta Pharmaceuticals	Motpoly XR®, formoterol fumarate

Please direct any questions concerning this non-compliance decision to the appropriate manufacturer.